Business Wire

CIVIL-SOCIETY-20

22.3.2020 18:51:13 CET | Business Wire | Press release

Share
Urgent Statement by the Civil 20 to the G20 Virtual Summit on COVID-19: New Realities Require New Priorities

The following is a statement by Civil 20:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005022/en/

The events of this year alone, starting with the bushfires in Australia and moving to the outbreak of COVID-19, underscored the ever-growing complexity of our global shared challenges and expose the weaknesses of the current dominant economic system, and how it deepens inequalities between individuals and countries. We ask that G20 leaders recognize our new global reality and reorient this year’s G20 priorities towards building a more resilient global governance.

G20 leaders need to uphold the principles of human rights, civic engagement, and democracy. As the crisis develops, the C20 observes with great alarm the continued deterioration of the situation for many vulnerable groups in different societies. Governments must protect and extend medical care to all people without leaving anyone behind.

The infodemic surrounding the disease is equally fatal to the virus. The C20 stands in solidarity with communities suffering as a result of different governments’ lack of transparency. Governments are accountable in their response to the crisis, and work on empowering local communities and civil society actors in responding to the outbreak.

We can learn from previous public health emergencies the importance of quality care continuum, protection of human rights, anti-discrimination and isolation of people living with the diseases and affected communities. COVID-19 is a sobering reminder that we need to increase investment in what we know works: strong international partnerships, building health care delivery systems that reach everyone, research and development, and an approach to care that prioritizes the most marginalized. The C20 urges that G20 leaders consider the recommendations in the statement on pandemic preparedness released jointly with the Business 20, Labor 20, Think 20, Women 20 and Youth 20.

Another emerging lesson out of this emergency, is that hyper-globalization of our supply chains is making our trade systems extremely vulnerable to shocks. The C20 cautions G20 leaders against the ongoing attempts in trade agreement negotiations to open “health markets” to foreign investors and competition, turning health systems into yet another investment opportunity. We worry that the divide between those who can afford healthcare and those who cannot will be exacerbated.

The C20 warns that inequalities will ensue as a consequence of the outbreak. Labor policies need to be put in place to address the needs of the most vulnerable, who cannot afford to sit at home, and prepare for the expected rise in working poverty, especially in countries with a high informal economy, where women are over-represented.

The world is in need of multilateral coordination of an effective response to the economic crisis that provides adequate fiscal and monetary stimulus, while safeguarding liquidity from misuse by speculative activities. A fairly designed stimulus package should take into account not only the interest of businesses and SMEs, but also households, workers, and the most vulnerable.

A problem with multiple dimensions requires a solution by multiple actors. Members of Civil Society and humanitarian NGOs continue to face tightened financial restrictions due to risk and cost aversion by banks in complying with FATF regulations. Such financial exclusion limits our ability to respond to global emergencies.

We implore the G20 Leaders to take immediate action in responding to the substantial impact on education and the dwindling prospects of ensuring access. The world is entirely unequipped to maintain a promise of “education for all”; particularly in contexts where classrooms can no longer provide a safe environment for learning.

The C20 calls on G20 leaders to expand this year’s G20 priorities to vigilantly respond to the changes in the labor market through expanding social protection systems, ensure digital and eLearning is accessible across, prioritize child online safety, address rising risks to debt sustainability in emerging markets as they face urgent financing needs to improve health systems capacity to respond to the COVID-19 outbreak, including debt relief and attending to their exposure to volatile capital flows.

Civil Society 20 (C20) is one of the eight official Engagement Groups of the G20. It provides a platform of Civil Society Organizations around the world to bring forth a non-government and non-business voice.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye